| Zaja, Francesco |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma |
|
|
| Recruiting | 3 | 300 | Europe, RoW | R-pola-mini-CHP, R-mini-CHOP | Nordic Lymphoma Group, Roche Pharma AG | DLBCL, Diffuse Large B Cell Lymphoma | 12/25 | 12/28 | | |
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML |
|
|
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Terminated | 2 | 22 | Europe | Venetoclax, ABT-199/GDC-0199 | Fondazione Italiana Linfomi - ETS | T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | 03/20 | 02/23 | | |
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL |
|
|
| Active, not recruiting | 2 | 16 | Europe | Carfilzomib, Lenalidomide, Dexamethasone | Fondazione Italiana Linfomi ONLUS | Mantle Cell Lymphoma | 12/20 | 12/22 | | |
NCT04251065: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH |
|
|
| Active, not recruiting | 2 | 8 | Europe | Daratumumab, Darzalex | Fondazione Italiana Linfomi ONLUS | Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | 12/21 | 11/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Recruiting | 2 | 90 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 06/24 | 07/27 | | |
Phoenix, NCT05924100: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD |
|
|
| Recruiting | 2 | 22 | Europe | Luspatercept Injection [Reblozyl] | Associazione Qol-one | Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia | 12/24 | 12/29 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
| Completed | 2 | 41 | Europe, Japan, US, RoW | Placebo, TAK-079 | Takeda | Primary Immune Thrombocytopenia | 04/24 | 04/24 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
|
|
| Recruiting | N/A | 15 | Europe | Venetoclax, Azacitidine, Decitabine | Ospedale Maggiore Di Trieste | Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax | 09/20 | 09/20 | | |
| Recruiting | N/A | 12 | Europe | Immune checkpoint inhibitor, radiotherapy | Ospedale Maggiore Di Trieste | Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy | 09/20 | 09/20 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
| Recruiting | N/A | 861 | Europe | Observation | Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation | Idiopathic Thrombocytopenic Purpura | 07/23 | 07/23 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
